Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain
Keyword(s):
Erlotinib and gefitinib, tyrosine kinase inhibitors used to block EGFR (epidermal growth factor receptor) signalling in cancer, are thought to bind only the active conformation of the EGFR-TKD (tyrosine kinase domain). Through parallel computational and crystallographic studies, we show in the present study that erlotinib also binds the inactive EGFR-TKD conformation, which may have significant implications for its use in EGFR-mutated cancers.
1995 ◽
Vol 38
(18)
◽
pp. 3482-3487
◽
2006 ◽
Vol 12
(14)
◽
pp. 4416s-4420s
◽
2020 ◽
Vol 97
◽
pp. 107564
2014 ◽
Vol 88
(12)
◽
pp. 2321-2322
◽
1989 ◽
Vol 264
(19)
◽
pp. 11346-11353
◽
2021 ◽
2005 ◽
Vol 62
(4)
◽
pp. 1036-1043
◽